Inactivation of BRCA1 and BRCA2 in ovarian cancer - PubMed (original) (raw)
. 2002 Sep 18;94(18):1396-406.
doi: 10.1093/jnci/94.18.1396.
Affiliations
- PMID: 12237285
- DOI: 10.1093/jnci/94.18.1396
Inactivation of BRCA1 and BRCA2 in ovarian cancer
Jeffrey L Hilton et al. J Natl Cancer Inst. 2002.
Abstract
Background: Although BRCA1 and BRCA2 play important roles in hereditary ovarian cancers, the extent of their role in sporadic ovarian cancers and their mechanisms of inactivation are not yet well understood. Our goal was to characterize BRCA2 mutations and mRNA expression in a group of ovarian tumors previously evaluated for BRCA1 mutations and mRNA expression.
Methods: The tumors of 92 unrelated women with "ovarian" cancer (i.e., ovarian, peritoneal, or fallopian tube cancer) were screened for BRCA2 null mutations using a protein truncation test. Methylation-specific polymerase chain reaction (PCR) was used to examine the BRCA2 promoter for hypermethylation in tumors that did not express BRCA2 mRNA. All statistical tests were two-sided.
Results: Nine tumors had a germline (n = 5) or somatic (n = 4) BRCA2 mutation; each was associated with loss of heterozygosity. All of the somatic (1445delC, E880X, 4286del8, and 5783delT) and one of the germline (5984ins4) mutations were unique to this study. One tumor had somatic mutations in both BRCA1 and BRCA2. Two tumors are, to our knowledge, the first cases of germline BRCA2-associated peritoneal cancer. Twelve additional tumors lacked detectable BRCA2 mRNA, but the BRCA2 promoter was hypermethylated in only one of them, suggesting that other mechanisms effect transcriptional silencing of BRCA2. Tumors lacking BRCA1 mRNA were more likely to lack BRCA2 mRNA than tumors expressing BRCA1 mRNA (P<.001). Overall, 82% (95% confidence interval [CI] = 74% to 90%) of the tumors contained alterations in BRCA1, BRCA2, or both genes. Of 41 informative tumors with some alteration in BRCA2, 36 also had an alteration in BRCA1. The frequency, but not the mechanism, of BRCA1 or BRCA2 dysfunction in ovarian cancer was independent of family history.
Conclusions: Multiple mechanisms cause nearly universal dysfunction of BRCA1 and/or BRCA2 in hereditary and sporadic ovarian carcinoma. Ovarian cancers with BRCA2 dysfunction often have simultaneous BRCA1 dysfunction.
Similar articles
- Skewed X chromosome inactivation and breast and ovarian cancer status: evidence for X-linked modifiers of BRCA1.
Lose F, Duffy DL, Kay GF, Kedda MA, Spurdle AB; Kathleen Cuningham Foundation Consortium for Research into Familial Breast Cancer; Australian Ovarian Cancer Study Management Group. Lose F, et al. J Natl Cancer Inst. 2008 Nov 5;100(21):1519-29. doi: 10.1093/jnci/djn345. Epub 2008 Oct 28. J Natl Cancer Inst. 2008. PMID: 18957670 - Epigenetic factors controlling the BRCA1 and BRCA2 genes in sporadic ovarian cancer.
Chan KY, Ozçelik H, Cheung AN, Ngan HY, Khoo US. Chan KY, et al. Cancer Res. 2002 Jul 15;62(14):4151-6. Cancer Res. 2002. PMID: 12124354 - Frequency of BRCA1 dysfunction in ovarian cancer.
Geisler JP, Hatterman-Zogg MA, Rathe JA, Buller RE. Geisler JP, et al. J Natl Cancer Inst. 2002 Jan 2;94(1):61-7. doi: 10.1093/jnci/94.1.61. J Natl Cancer Inst. 2002. PMID: 11773283 - Peritoneal carcinoma in women with genetic susceptibility: implications for Jewish populations.
Casey MJ, Bewtra C. Casey MJ, et al. Fam Cancer. 2004;3(3-4):265-81. doi: 10.1007/s10689-004-9554-y. Fam Cancer. 2004. PMID: 15516851 Review. - [Management of hereditary ovarian cancer].
Joó JG, Ládi S, Nagy BZ, Langmár Z. Joó JG, et al. Orv Hetil. 2011 Oct 2;152(40):1596-608. doi: 10.1556/OH.2011.29218. Orv Hetil. 2011. PMID: 21945869 Review. Hungarian.
Cited by
- Hypermethylation of the BRCA2 gene promoter and its co-hypermethylation with the BRCA1 gene promoter in patients with breast cancer.
Fishchuk L, Rossokha Z, Lobanova O, Cheshuk V, Vereshchako R, Vershyhora V, Medvedieva N, Dubitskaa O, Gorovenko N. Fishchuk L, et al. Cancer Biomark. 2024;40(3-4):275-283. doi: 10.3233/CBM-230458. Cancer Biomark. 2024. PMID: 39177589 Free PMC article. - Unraveling noncoding DNA variants and epimutations: a paradigm shift in hereditary cancer research.
Ibrahim MB, Flanagan J, Ibrahim T, Rouleau E. Ibrahim MB, et al. Future Oncol. 2024;20(18):1289-1298. doi: 10.2217/fon-2023-0665. Epub 2024 May 9. Future Oncol. 2024. PMID: 38722139 Review. - Predicting Prognosis and Platinum Resistance in Ovarian Cancer: Role of Immunohistochemistry Biomarkers.
Atallah GA, Kampan NC, Chew KT, Mohd Mokhtar N, Md Zin RR, Shafiee MNB, Abd Aziz NHB. Atallah GA, et al. Int J Mol Sci. 2023 Jan 19;24(3):1973. doi: 10.3390/ijms24031973. Int J Mol Sci. 2023. PMID: 36768291 Free PMC article. Review. - Clinical Impact of Next-Generation Sequencing Multi-Gene Panel Highlighting the Landscape of Germline Alterations in Ovarian Cancer Patients.
Gurioli G, Tedaldi G, Farolfi A, Petracci E, Casanova C, Comerci G, Danesi R, Arcangeli V, Ravegnani M, Calistri D, Zampiga V, Cangini I, Fonzi E, Virga A, Tassinari D, Rosati M, Ulivi P, De Giorgi U. Gurioli G, et al. Int J Mol Sci. 2022 Dec 13;23(24):15789. doi: 10.3390/ijms232415789. Int J Mol Sci. 2022. PMID: 36555431 Free PMC article. - Application of Multilayer Evidence for Annotation of C-Terminal BRCA2 Variants.
Butz H, Papp J, Bozsik A, Krokker L, Pócza T, Oláh E, Patócs A. Butz H, et al. Cancers (Basel). 2021 Feb 20;13(4):881. doi: 10.3390/cancers13040881. Cancers (Basel). 2021. PMID: 33672545 Free PMC article.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical
Molecular Biology Databases
Miscellaneous